Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.

@article{Schnitzer2011LongtermOS,
  title={Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.},
  author={Thomas J. Schnitzer and Nancy E. Lane and Charles A Birbara and Michael D. Smith and Susan Lee Simpson and M. T. Brown},
  journal={Osteoarthritis and cartilage},
  year={2011},
  volume={19 6},
  pages={639-46}
}
OBJECTIVE This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients with OA knee pain. DESIGN The current study (clinicaltrials.gov identifier: NCT00399490) was a multicenter, phase II, open-label, multiple-dose extension of an earlier randomized clinical trial. All patients (N=281) received infusions of tanezumab 50μg/kg on Days 1 and 56 with subsequent… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Tanezumab for treatment of knee osteoarthritis pain

  • NE Lane, TJ Schnitzer, CA Birbara, M Mokhtarani, DL Shelton, MD Smith
  • N Engl J Med 2010;363:1521e31
  • 2010

Similar Papers

Loading similar papers…